Holen Sie sich die Stockscreener-App
8.14
0.37%
0.03
Handel nachbörslich:
8.14
Schlusskurs vom Vortag:
$8.11
Offen:
$8.16
24-Stunden-Volumen:
1.13M
Relative Volume:
1.36
Marktkapitalisierung:
$602.10M
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-2.8166
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
+1.94%
1M Leistung:
-8.95%
6M Leistung:
-65.36%
1J Leistung:
-60.02%
1-Tages-Spanne:
$7.89
$8.349
1-Wochen-Bereich:
$7.85
$9.37
52-Wochen-Spanne:
$7.16
$27.24
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.14 | 602.10M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings - Defense World
Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR) - Defense World
Research Analysts Set Expectations for Xencor Q2 Earnings - Defense World
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Nigeria
Q4 Earnings Forecast for Xencor Issued By William Blair - Defense World
What is Wedbush’s Estimate for Xencor Q4 Earnings? - Defense World
Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa
Xencor Reports First Quarter 2025 Financial Results - BioSpace
Xencor: Q1 Earnings Snapshot - MySA
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
(XNCR) Technical Data - news.stocktradersdaily.com
Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush - Defense World
Healthy Upside Potential: Xencor Inc (XNCR) - Sete News
Xencor reports positive trial results for inflammatory bowel disease treatment - MSN
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Wells Fargo & Company MN Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Analyzing Xencor Inc (XNCR) After Recent Trading Activity - knoxdaily.com
Trading Day Triumph: Xencor Inc (XNCR) Ends at 10.58, a -0.19 Surge/Plunge - DWinneX
Is Xencor Inc (XNCR) a good investment opportunity? - uspostnews.com
Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor Announces Promising Phase 1 Study Results - TipRanks
Raymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Stu - GuruFocus
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - BioSpace
Xencor posts trial data for bowel disease drug (XNCR:NASDAQ) - Seeking Alpha
Xencor advances ulcerative colitis treatment into Phase 2b study - Investing.com
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Study | XNCR Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Is Xencor (NASDAQ:XNCR) A Risky Investment? - simplywall.st
LPL Financial LLC Has $452,000 Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Gaining Ground: Xencor Inc (XNCR) Closes Higher at 10.87, Up 2.07 - DWinneX
It is Poised to be a Bull Market for Xencor Inc (XNCR) - Sete News
Equities Analysts Issue Forecasts for Xencor Q1 Earnings - Defense World
Is the Xencor Inc (NASDAQ:XNCR) stock an investment opportunity? - uspostnews.com
Invesco Ltd. Sells 156,130 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
JPMorgan Chase & Co. Sells 9,291 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor Inc Shares Are Up -44.42% Since The Beginning Of The Year - Marketing Sentinel
Xencor Inc (XNCR) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Xencor (NASDAQ:XNCR) Now Covered by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation - Nasdaq
William Blair starts Xencor stock with Outperform rating By Investing.com - Investing.com Canada
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
Xencor (XNCR) Receives Outperform Rating from William Blair | XN - GuruFocus
William Blair starts Xencor stock with Outperform rating - Investing.com
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):